SEC Form 4 · accession 0001209191-18-008213
BELLICUM PHARMACEUTICALS, INC · BLCM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William Grossman
Officer — Sr. VP, Chief Medical Officer
Period of report
Feb 5, 2018
Accepted (ET)
Feb 7, 2018 · 6:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001358403
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 5, 2018 | A | 30,000 | $0.00 | A | 30,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F2 | $5.61 | Feb 5, 2018 | A | 175,000 | A | — | Feb 4, 2028 | Common Stock | 175,000 | 175,000 | D |
Explanation of responses
- F1Represents grant of restricted stock units payable solely in common stock that vest in four equal annual installments on each anniversary of February 5, 2018.
- F225% of the shares subject to the stock option vest and become exercisable on February 5, 2019, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.